Mueller Brian

EVP, Chief Financial OfficerBIOMARIN PHARMACEUTICAL INC (BMRN) · full profile →Form 4 · filed May 31, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$376K
Net Open-Market Flow
-$376K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 30, 2024Sell(S)5K$75.19$376K72K
May 30, 2024Option exercise(M)5K$63.10$316K77K
Apr 30, 2024Grant(A)300$68.65$21K72K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 30, 2024Option exercise(M)5K$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001048477-24-000114) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.